title: ERCC1 and personalized medicine in lung cancer.
abstract: Excision repair cross-complementing group 1 (ERCC1) is known to be a key player in nucleotide excision repair (NER) pathway. Its prognostic or predictive relevance has been extensively investigated in cancer patients including non-small-cell lung cancer. However, several questions should be addressed before its clinical application as biomarker for patient classification or guiding platinum treatment.
authors.affiliation: Center for Lung Cancer, Inha University Hospital and Department of Internal Medicine, School of Medicine, Inha University, Incheon, South Korea.
authors.forename: Jeong Seon
authors.initials: JS
authors.lastname: Ryu
authors.affiliation: Center for Lung Cancer, Inha University Hospital and Department of Internal Medicine, School of Medicine, Inha University, Incheon, South Korea.
authors.forename: Azra
authors.initials: A
authors.lastname: Memon
authors.affiliation: Center for Lung Cancer, Inha University Hospital and Department of Internal Medicine, School of Medicine, Inha University, Incheon, South Korea.
authors.forename: Seul-Ki
authors.initials: SK
authors.lastname: Lee
keywords: Biomarker; excision repair cross-complementing group 1 (ERCC1); non-small-cell lung cancer; personalized medicine